Skip to main content
Multiple Sclerosis Journal - Experimental, Translational and Clinical logoLink to Multiple Sclerosis Journal - Experimental, Translational and Clinical
. 2016 Feb 11;2:2055217316631762. doi: 10.1177/2055217316631762

Geographic variations of multiple sclerosis prevalence in France: The latitude gradient is not uniform depending on the socioeconomic status of the studied population

Philippe Ha-Vinh 1,, Stève Nauleau 2, Marine Clementz 3, Pierre Régnard 4, Laurent Sauze 5, Henri Clavaud 6
PMCID: PMC5433399  PMID: 28607717

Abstract

Background

In France, two studies analysed multiple sclerosis prevalence nationwide: one was carried out in farmers, and the other one in employees. A south-north gradient of prevalence was found solely in farmers.

Objective

In order to better describe the latitude gradient in France, which is not uniform depending on the studied population, we assessed whether a gradient exists in another population than farmers and employees: independent workers. The same methods of case ascertainment have been used.

Methods

Altogether 4,165,903 persons insured by the French health insurance scheme for independent workers were included. We searched the database for (a) long term disease status ‘multiple sclerosis’, (b) domicile, (c) gender and (d) age.

Results

A total of 4182 cases of multiple sclerosis were registered giving a prevalence of 100.39/100,000. Adjustment by age and sex and spatial smoothing with a Bayesian analysis showed a gradual increase of prevalence from the southwest to the northeast of France. Standardised morbidity ratio was correlated with latitude and longitude (p<0.0001; p = 0.0031; adjusted R2 = 0.3038).

Conclusion

A discrepancy of geographic distribution between farmers and independent workers on the one hand and employees on the other cannot be attributable to environment. Assuming that socioeconomic status by itself is not associated with multiple sclerosis risk, employees’ geographic mobility at adulthood for professional reasons could have interfered with the gradient effect.

Keywords: Multiple sclerosis, prevalence, Bayesian analysis, geographic distribution, epidemiology, socioeconomic status

Introduction

In Europe and North America the previously reported latitudinal gradient of incidence or prevalence for multiple sclerosis seems to have disappeared or decreased by comparison with prior published series of geographic data.14 In France, a previous study found a southwest-northeast gradient of prevalence in farmers,5 and a subsequent study did not find such a gradient in employees.6 Change in such a short period of time cannot be attributable to improvement in diagnosis accuracy or case ascertainment, nor to a change in environmental factors. Labour mobility might be of relevance, economic migrations in employees diluting the spatial repartition of multiple sclerosis susceptibility genes.4 Geographic mobility for job search could have interfered with the gradient effect as migration at adulthood (for instance for professional reasons) may contribute to modifying multiple sclerosis prevalence where migrants have moved; the migrants may bring (or not bring) the latent disease along with them when moving at adulthood, as the risk of developing (or not developing) multiple sclerosis has already been largely determined by the age of 15 years.7,8

In order to better describe the latitude gradient in France and to show that it is not uniform depending on the socioeconomic status of the studied population, we assessed whether the southwest-northeast gradient of multiple sclerosis that disappeared in employees, and that still exists in farmers, persists in another population which is also more sedentary than the employees: independent workers and their families.

Materials and methods

Setting and target population

The health insurance fund for independent workers or Régime Social des Indépendants (RSI) is the third main statutory health insurance scheme in France. It is dedicated only to independent workers and their families (i.e. independent workers from small businesses in the manufacturing industry, craft industry and commercial industry, as well as workers from learned professions). It covers 6% of the French population, spread all over the French territory. French territory is divided in 101 French administrative areas called départements (named ‘departments' hereafter) including islands and overseas departments. Neighbouring departments are grouped into regions. The RSI covers all the departments and regions of the French territory. The target population was the population covered in the course of 2013.

Study type

Our study is a cross-sectional study carried out on two national databases based on the whole of France:

  1. TITAM. The administrative database of benefits in kind and in cash provided by the health insurance (named ‘benefit' hereafter).

  2. ARCHIMED. The medico-administrative database of the insured who are entitled, through health insurance, to exemption from their side copayment due to a long-term disease status granted by the French National Health Insurance System.a

Statistical unit

The statistical unit is the person who received the benefit. It is identified in the database by the insured person’s single social security number and the beneficiary’s ranking, if the person who received the benefit is not the actual insured person but one of their beneficiaries.

Included population

All persons who received a benefit in 2013 are included in the study, i.e. 4,165,903 persons.

Outcome

The outcome was the number of included persons who had, or had had, a long-term disease statusa of multiple sclerosis granted by the French National Health Insurance System. Those persons are identified in the medico-administrative database of long-term disease status as having, or having had, multiple sclerosis, whatever the date of recognition as a long-term disease before 31 December 2013, even if the long-term disease agreement has not been renewed till this date (expired long-term disease agreements which are not renewed are kept in the medico-administrative database as long as the person is affiliated to RSI, even if they do not receive any benefit at all for years or decades after disease onset). Crude prevalence rates were calculated as the number of persons who received a benefit of any kind in 2013 and had, or had had, a long-term disease status for multiple sclerosis granted by the French National Health Insurance System per 100,000 persons who received a benefit of any kind in 2013.

We calculated the crude prevalence rates in each modality of the independent variables.

Regional level (including islands and overseas departments)

Pearson correlation was used to examine the relationship of crude prevalence rate and decimal degrees of north latitude (in absolute terms to take into account the southern hemisphere). Latitudes were those of capital cities of the 28 regions (préfectures de region).

Departmental level (islands and overseas departments excluded)

We applied the indirect method of standardisation: we calculated the expected number of cases in each department of France if they had the same age and sex-specific prevalence rates as the whole included population; then we divided the observed number of cases by the expected number of cases to provide the crude standardised morbidity ratio (SMR) in each department.

A spatial smoothing of the crude SMRs was performed accounting for differences in department size and their spatial correlation – adjacent departments may not be independent as their inhabitants probably share the same risk factors for multiple sclerosis. To that purpose, a Bayesian model was used.9 This spatial smoothing reassessed the local values: the smaller the number of observed cases in a department, the more the smoothed value was influenced by the national reference value. It also took into consideration a spatial component by borrowing strength from neighbouring departments using a contiguity matrix. The extent of smoothing was determined by the size of the crude SMR, its precision and the underlying relative risk distribution. Thus the extent of smoothing was totally determined by the data.10

However this mapping method is most useful for capturing gradual regional changes in disease rates and is less useful in detecting abrupt localised changes indicative of clustering.11 So, a SMR spatial association measurement was also implemented using the G statistic.12 The G statistic (Getis-Ord Gi) identifies statistically significant spatial clusters of high values (hot spots) and low values (cold spots), highlighting the existence of spatial structures. To create a hot spot, the territory concerned with respectively high or low value of the SMR must be surrounded by other entities also associated with high or low values.

In addition, a multiple linear regression model (ordinary least squares (OLS)) was used to examine the relationship of crude SMR with latitude and longitude. Latitudes and longitudes were those of capital cities of the departments (préfectures de département). As an outlier the department of Lozère was excluded.

Independent variable (varying factors)

  1. Insured party’s age in 2013 broken down by age groups.

  2. Insured party’s gender: men, women.

  3. Insured party’s domicile in 2013 broken down by department and region of France, with the decimal degrees of latitude and longitude of the capital cities of each department and region.

Statistical analysis tools

  1. ArcGIS 10.1 (which includes a graphical user interface application called ArcMap) for estimate of spatial structures and cartographic representations.912

  2. SAS 9.3 for data processing: calculation of standardised morbidity ratio, non-spatial and spatial smoothing (GLIMMIX procedure performs estimation and statistical inference for generalized linear mixed models or GLMMs).

Ethics

The data were entirely anonymised before being sent for analysis to the research group.

For ethics purposes, the database study was approved by the Commission nationale de l'informatique et des libertés (CNIL) (French Data Protection Authority) (dossier no. 342521, amendment 2) and the study protocol was approved by the in-house RSI committee responsible for the research.

Results

Description of the included population

Demographic characteristics are shown in Tables 1 and 2.

Table 1.

Multiple sclerosis prevalence in France; 4,165,903 beneficiaries in 2013 including 4182 prevalent cases; crude prevalence rates by domicile region, age, and gender.

Domicile regions sorted by increasing multiple sclerosis crude prevalence rates Capital city of the region Decimal degrees of north latitude of the capital city of the region in absolute terms Included population (n = 4,165,903) Included population with the long term disease status ‘multiple sclerosis’ (n = 4182) Crude prevalence rates per 100,000 persons
Guyane Cayenne 4.9224 8568 0 0
Not filled 5625 0 0
Mayotte Mamoudzou 12.7809 7 0 0
Saint Pierre et Miquelon Saint Pierre 46.7786 1 0 0
Reunion Saint-Denis 20.9203 47,197 9 19
Martinique Fort-de-France 14.6161 19,446 7 36
Guadeloupe Basse-Terre 17.3026 28,582 11 38
Corse Ajaccio 41.9192 25,231 21 1st quartile 83
Languedoc-Roussillon Montpellier 43.6108 232,144 201 87
Provence-Alpes-Cote d'Azur Marseille 43.2965 427,068 379 89
Aquitaine Bordeaux 44.8378 267,659 242 90
Pays-de-Loire Nantes 47.2184 229,910 212 92
Rhone-Alpes Lyon 45.7640 455,672 421 92
Midi-Pyrenees Toulouse 43.6047 226,029 213 94
Ile-de-France Paris 48.8566 625,725 626 100
Auvergne Clermont-Ferrand 45.7772 97,337 100 103
Limousin Limoges 45.8336 50,735 53 104
Poitou-Charentes Poitiers 46.5802 133,370 140 105
Centre Orléans 47.9030 150,436 162 108
Picardie Amiens 49.8941 95,044 105 110
Bretagne Rennes 48.1173 226,053 252 111
Haute-Normandie Rouen 49.4432 98,206 113 115
Bourgogne Dijon 47.3220 105,501 128 3rd quartile 121
Basse-Normandie Caen 49.1829 97,892 119 122
Alsace Strasbourg 48.5734 83,052 102 123
Nord-pas-de-Calais Lille 50.6293 185,288 236 127
Lorraine Metz 49.1193 107,337 139 129
Franche-Comte Besançon 47.2378 66,724 91 136
Champagne-ardenne Châlons-en-Champagne 48.9567 70,064 100 143
Age, years
Mean 42.69 52.44
Standard deviation 23.02 14.25
Median 44.00 52.00
Minimum 0 0
Maximum 113 101
0–13 637738 4 1
14–29 544871 181 33
30–39 540281 611 113
40–49 753382 1010 134
50–59 671542 1037 154
60–69 510889 845 165
70–79 265782 359 135
80 and above 241418 135 56
Gender
Women 1791771 2517 140
Men 2374132 1665 70

Source: Health insurance fund for independent workers – whole of France.

Table 2.

Multiple sclerosis prevalence in France; 4,165,903 beneficiaries in 2013 including 4182 prevalent cases; crude prevalence rates by domicile department.

Included population (n = 4,165,903) Included population with the long term disease status ‘multiple sclerosis’ (n = 4182) Crude prevalence rates per 100,000 persons
Domicile department sorted by increasing multiple sclerosis crude prevalence rates (zip-code and name)
973 Guyane 8568 0 0
975 Saint Pierre et Miquelon 1 0 0
976 Mayotte 7 0 0
Not filled Not filled 5625 0 0
974 Reunion 47,197 9 19
972 Martinique 19,446 7 36
971 Guadeloupe 28,582 11 38
11 Aude 30,735 13 42
53 Mayenne 18,037 12 67
13 Bouches du Rhone 135,382 93 69
82 Tarn et Garonne 20,239 14 69
32 Gers 15,649 11 10th percentile 70
73 Savoie 39,580 28 71
40 Landes 31,520 23 73
65 Hautes Pyrenees 18,844 15 80
7 Ardeche 24,784 20 81
79 Deux Sevres 23,470 19 81
63 Puy de Dome 43,224 35 81
26 Drome 37,721 31 82
34 Herault 95,182 79 83
20 Corse 25,231 21 83
64 Pyrenees Atlantiques 53,471 45 84
24 Dordogne 37,866 32 85
49 Maine et Loire 47,228 40 85
38 Isere 81,585 70 86
92 Hauts de Seine 85,618 74 86
12 Aveyron 24,035 21 87
93 Seine Saint Denis 60,083 53 88
19 Correze 18,049 16 89
1 Ain 37,962 34 90
72 Sarthe 30,096 27 90
30 Gard 60,747 55 91
31 Haute Garonne 89,346 82 92
80 Somme 28,124 26 92
9 Ariege 12,772 12 94
95 Val d'Oise 49,529 47 95
54 Meurthe et Moselle 35,504 34 96
74 Haute Savoie 64,592 62 96
84 Vaucluse 47,917 46 96
33 Gironde 118,296 114 96
83 Var 101,538 98 97
66 Pyrenees Orientales 39,325 38 97
56 Morbihan 57,544 56 97
44 Loire Atlantique 86,840 85 98
6 Alpes Maritimes 113,197 111 98
78 Yvelines 66,721 66 99
94 Val de Marne 66,071 66 100
71 Saone et Loire 37,028 37 100
85 Vendee 47,709 48 101
28 Eure et Loir 22,734 23 101
4 Alpes de Haute Provence 14,795 15 101
45 Loiret 36,257 37 102
55 Meuse 9765 10 102
69 Rhone 117,866 122 104
37 Indre et Loire 36,652 38 104
10 Aube 16,308 17 104
42 Loire 51,582 54 105
16 Charente 26,745 28 105
77 Seine et Marne 64,656 68 105
47 Lot et Garonne 26,506 28 106
87 Haute Vienne 23,638 25 106
60 Oise 40,453 43 106
75 Paris 180,436 192 106
50 Manche 32,740 35 107
58 Nievre 13,760 15 109
35 Ille et Vilaine 65,363 72 110
17 Charente Maritime 56,642 63 111
15 Cantal 12,528 14 112
5 Hautes Alpes 14,239 16 112
76 Seine Maritime 63,944 72 113
86 Vienne 26,513 30 113
18 Cher 19,401 22 113
91 Essonne 52,611 60 114
81 Tarn 29,768 34 114
36 Indre 13,975 16 114
68 Haut Rhin 32,083 37 115
8 Ardennes 15,597 18 115
59 Nord 116,070 134 115
29 Finistere 58,681 68 116
70 Haute Saone 14,497 17 117
3 Allier 24,249 29 120
27 Eure 34,262 41 120
41 Loir et Cher 21,417 26 121
61 Orne 19,090 24 126
22 Cotes d'Armor 44,465 56 126
43 Haute Loire 17,336 22 127
67 Bas Rhin 50,969 65 128
14 Calvados 46,062 60 130
23 Creuse 9048 12 133
21 Cote d'Or 32,704 44 135
2 Aisne 26,467 36 136
39 Jura 16,817 23 90th percentile 137
90 Territoire de Belfort 6356 9 142
25 Doubs 29,054 42 145
89 Yonne 22,009 32 145
62 Pas de Calais 69,218 102 147
52 Haute Marne 9457 14 148
57 Moselle 38,629 58 150
46 Lot 15,376 24 156
88 Vosges 23,439 37 158
51 Marne 28,702 51 178
48 Lozere 6155 16 260

Source: Health insurance fund for independent workers – whole of France.

The included population was made up of 4,165,903 persons of which 4182 had or had had a long term disease status for multiple sclerosis granted by the French National Health Insurance System. Their mean age was 42.69 years (standard deviation (SD) 23.02) and 52.44 years (SD 14.25) with 43.01% and 60.19% of women respectively. They were living in 28 regions and 101 departments. The smallest region (which is also a department) was Saint Pierre And Miquelon (one person; 0.00%) and the largest region was Ile-De-France (625,725 persons; 15.02%); the largest department was Paris (180,436 persons; 4.33%) (Tables 1 and 2).

Multiple sclerosis prevalence in the included population

Crude prevalence rates

Among RSI beneficiaries, multiple sclerosis national prevalence in France in 2013 was 4182 cases for 4,165,903 beneficiaries regardless of age, i.e. 100.39/100,000 beneficiaries (95% confidence interval (CI): 97.39–103.47), 140.48/100,000 beneficiaries in women (95% CI: 135.10–146.07) and 70.13/100,000 beneficiaries in men (95% CI: 66.84–73.58).

The prevalence rates according to age and sex are shown in Figure 1.

Figure 1.

Figure 1.

Multiple sclerosis prevalence in France; 4,165,903 beneficiaries in 2013 including 4182 prevalent cases; crude prevalence rates per 100,000 persons by age and gender.

Source: Health insurance fund for independent workers – whole of France.

RSI population size, crude prevalence rate, and decimal degrees of latitude in absolute terms for each of the 28 regions of the French territory are given in Table 1. Latitude (in absolute terms to take into account the southern hemisphere) was strongly correlated with crude prevalence rate (r = 0.68, p < 0.0001) in the 28 regions.

Regions where multiple sclerosis prevalence was below the 1st quartile (84.91/100,000) and regions where multiple sclerosis prevalence was above the 3rd quartile (118.20/100,000) are shown in Table 1.

Departments where multiple sclerosis prevalence was equal or below the 10th percentile (70.29/100,000) and departments where multiple sclerosis prevalence was equal or above the 90th percentile (136.77/100,000) are shown in Table 2.

SMR

The following analyses were performed excluding islands and overseas departments.

We mapped the crude SMRs at the French department level (Figure 2(a)).

Figure 2.

Figure 2.

Multiple sclerosis standardised prevalence ratio for each department of France; 4,165,903 beneficiaries in 2013 including 4182 prevalent cases: (a) crude standardised morbidity ratios (SMRs); (b) smoothed SMRs. Islands and overseas departments are not shown.

Source: Health insurance fund for independent workers – whole of France.

The Bayesian spatial smoothing of the crude SMRs captured the gradual regional changes in disease rates, revealing an obvious southwest/northeast gradient that visually clearly appeared when the smoothed SMRs were mapped (Figure 2(b)).

Two spatial structures with similar levels of SMR, were highlighted in Figure 3: a spatial cluster of low values (cold spots with a GiZScore below –2.58 SD) in the southwest for Haute Garonne and Gers and a spatial cluster of high values (hot spots with a GiZScore above + 2.58 SD) in the northeast for Territoire de Belfort, Haute Saone, Haute Marne and Aube.

Figure 3.

Figure 3.

Multiple sclerosis standardised prevalence ratio for each department of France; 4,165,903 beneficiaries in 2013 including 4182 prevalent cases. Standardised morbidity ratio (SMR) spatial association measurement using the G statistic detecting spatial disease clustering (islands and overseas departments are not shown).

Source: Health insurance fund for independent workers – whole of France.

Confirming the visual approach, the OLS multiple linear regression model showed the existence of a south-north effect and a west-east side effect. Crude SMR was correlated with latitude (p < 0.0001) and with longitude (p = 0.0031) in the departments of France: adjusted R2 = 0.3038; regression equation:

SMRpredicted=-1.618+0.056×latitude   +0.023×longitude

The OLS simple linear regression model, assessing the association of crude SMR with latitude, highlights the south-north effect: p < 0.0001; adjusted R2 = 0.2408; regression equation:

SMRpredicted=-1.476+0.054×latitude

Figure 4 shows the model fit and summarises some of the statistics.

Figure 4.

Figure 4.

Fit plot showing the model fit and summarising some of the statistics, for the simple linear regression model assessing the association of multiple sclerosis standardised prevalence ratio (SMR) with latitude (degrees north, based on prefecture cities), for each department of France (islands and overseas departments excluded).

Source: Health insurance fund for independent workers – whole of France.

Discussion

Analysing 4,165,903 independents workers and their families out of the 65,543,000 inhabitants of France (6%), our study completes the two previous French studies carried out in farmers and in employees (respectively 5% and 87% of the French population) and thus gives a complete overview of multiple sclerosis prevalence in France.5,6

Accounting for the age, sex, size difference and autocorrelation between geographic entities our study found a latitudinal gradient of prevalence in the population of independents workers and their families, similarly to that which was found for farmers and their families,5 but contrary to findings for employees and their families.6 Three explanations can be proposed for the modification of the gradient effect in employees: compared to the other two populations, they are (a) younger, which implies that the onset of the disease is more recent; (b) more prone to move for professional reasons (Figure 5) as farmers are attached to their land and independents can create their own employment locally (geographic mobility in adulthood interferes with the gradient effect);4 and (c) less exposed to outdoor work (ultraviolet (UV) radiation gradient over France also interferes).1317

Figure 5.

Figure 5.

Departmental mobility of French populations according to their status (farmer, independent worker, employee).

Source: Institut national de la statistique et des études économiques (INSEE), 2008.

Moreover our study found a geographic clustering of the disease similar to that which was already found by Kurtzke and Delasnerie-Lauprêtre in 1986, indicating geographic stability of the clusters over time.18 It is therefore unlikely that the observed change in geography of multiple sclerosis for the population of employees in France was due to a change in an environmental factor as it would have affected the independent and agricultural workers populations in the same way. Nor can it be due to a difference in the level of disease investigation or a better accuracy in the survey methodology, as the same methods of case ascertainment have been used. Geographic mobility for job search or other professional reasons could have diluted the geographical repartition of prevalent cases in the population of employees.

In our study, the six departments with the lowest multiple sclerosis crude prevalence rates are islands or overseas departments. They present a high rate of inhabitants born outside metropolitan France, a high amount of sunshine, and the smallest numeric values of degrees of latitude in absolute terms (excluding Saint Pierre and Miquelon) (Table 1). This was not unexpected, given the lower frequencies of high-risk alleles for multiple sclerosis (e.g. In the human leukocyte antigen (HLA) class II group of genes, statistically, an association of multiple sclerosis with the HLA-DRB1*15:01-HLA-DQB1*06:02 haplotype has been demonstrated in northern European populations. Multiple sclerosis in African populations is characterized by greater haplotypic diversity and distinct patterns of linkage disequilibrium compared with northern Europeans.) in non-European-descent populations, the link between sun exposure and prevalence, and the significant positive correlation between latitude and prevalence worldwide.1317,19

In the study on salaried workers, the two regions with the lowest smoothed relative risk of multiple sclerosis prevalence (i.e. Ile de France and Provence Alpes Côte d’Azur) present a high non-Caucasian population share.4,6 A study conducted in the UK found the lowest multiple sclerosis prevalence rates in geographic areas where the non-UK born population share was the highest.20

A potential relationship between past exposure to sun and risk of multiple sclerosis has been observed by a number of authors.1317 So if multiple sclerosis was due to both genetics and environmental factors before adulthood,7,21 it would be of interest to be aware of each patient's birth place, besides their residence, in order to diminish the impact of migration flows on the geographic gradient; this could be the subject of another study.

To compare our findings with other results in the literature, it is important to note that there are two different types of studies: those using primary data from medical records, and those, as in our study, using secondary administrative data.

The first type of studies estimated multiple sclerosis prevalence to be (a) between 128 and 171/100,000 in Brittany22 (vs 132/100,000 in our study), (b) 188.2/100,000 in Lorraine23 (vs 153/100,000 in our study), and (c) between 110 and 149/100,000 in Haute Garonne24 (vs 109/100,000 in our study). The second type of study estimated multiple sclerosis prevalence to be (a) 65/100,000 in France in agricultural workers5 (vs 100.39/100,000 in our study) and (b) 94/100,000 in France in employees6 (vs 100.39/100,000 in our study). By comparing results from our study to these two previous studies using the same type of administrative data, there appears to be a temporal increase in multiple sclerosis prevalence although the increase observed could also be related to differences in the analysed populations.

Some authors reckon that at disease onset, during a period of a few months to several decades, disability results from focal inflammation (so that during this period of time immunomodulatory drugs are effective against disability). Thereafter, whatever the duration of this first phase, a diffuse degenerative process takes over for approximately seven years, with progression of irreversible disability (still with no therapeutic hope but for which treatments, to protect from neurodegeneration and enhance repair, are in phase III of clinical research).2529 Multiple sclerosis cases in our study are taken into account in the two phases of the disease, since recognition as a long-term disease status, with entitlement to exemption of copayment, requires either being treated with immunomodulatory drugs or permanent disability.b Although we could not determine individually to which phase of the disease our cases belonged, nevertheless we observed the highest relative frequency of prevalent cases, for women, in the 50–59 year-old age class and, for men, in the 60–69 year-old age class, which corresponds respectively to the median age to reach Kurtzke Disability Status Scalec (DSS) level of DSS 6 (women) and DSS 7 (men) according to the literature30 (Figure 1), two scores corresponding to the second phase of the disease (diffuse neurodegenerative process).25,26

Limitations of the current approach

The current approach, using claims by the insured party for recognition of a long term disease status, may have ignored clinically isolated syndromes as long as they do not respond to the administrative definition of a long term disease entitling to exemption of co-payment by the insured party.2 However, given that multiple sclerosis in itself, by its own natural history alone, entirely responds to the definition of a long term disease, as soon as a clinically definite multiple sclerosis has developed, the chances are high that the claim was made by the insured party; if so, whatever the clinical course of the disease at that time, this claim would have been immediately granted by RSI, even if it is a newly diagnosed case, since the disease is deemed to be a long-term disease and considered as such by the RSI.

Insured parties who did not perceive any benefit at all during the whole year 2013 were not included in our study (neither in the numerator nor in the denominator). It was assumed that they did not represent a significant part of the population affiliated to the health insurance system as benefits cover the entire spectrum of care, even for the most common diseases.

Given the risk of ecological fallacy, ecological data such as mobility, as a group, of farmers, employees, or independents, are limited in their ability to postulate conclusions at the individual level.

Conclusion

In France, in more sedentary and more exposed to outdoor work populations than employees, like farmers and independent workers, the north-south gradient of multiple sclerosis still exists while it has disappeared in employees. If we admit that the risk of developing multiple sclerosis is determined during childhood or adolescence and is not associated with socioeconomic status by itself,31,32 our findings support the assumption that geographic mobility for job search or for professional reasons at adulthood could influence the latitudinal gradient of prevalence for multiple sclerosis. The findings suggest that labour mobility could play a role in altering the north-south gradient that exists in France and more broadly that migrations could explain the recent observations of disappearance or decrease of the north-south gradient of multiple sclerosis in Europe and North America.

Acknowledgements

The authors would like to thank the RSI board for providing them with access to claims data to conduct this research, as well as members of the Support Group to Methods and Dissemination of Health Studies. The opinions expressed by authors do not necessarily reflect those of RSI.

Footnotes

a

Decree n°2011--77 of January 19th 2011 updating the list and medical criteria used for the definition of diseases giving right to the exemption of copayment by the insured party (JORF n°0017 of January 21st 2011 page 1287 text n° 20) ; medical criteria used for the definition of the long term disease ‘multiple sclerosis’. Multiple sclerosis is subject to the exemption of copayment by the insured party — when a disease-modifying immunomodulatory drug is being prescribed as the outcome of the medical check-up, even in the absence of permanent disability; — in case of a permanent disability (sometimes only consisting in asthenia or cognitive disturbances) requiring symptomatic treatment and justifying long term treatment) Initial exemption of copayment is given for 5 years, extendable.

b

Decree n°2011-77 of January 19th 2011 updating the list and medical criteria used for the definition of diseases giving right to the exemption of copayment by the insured party (JORF n°0017 of January 21st 2011 page 1287 text n° 20); medical criteria used for the definition of the long term disease ‘multiple sclerosis’. Multiple sclerosis is subject to the exemption of copayment by the insured party — when a disease-modifying immunomodulatory drug is being prescribed as the outcome of the medical check-up, even in the absence of permanent disability; — in case of a permanent disability (sometimes only consisting in asthenia or cognitive disturbances) requiring symptomatic treatment and justifying long term treatment) Initial exemption of copayment is given for 5 years, extendable.

c

Kurtzke Disability Status Scale (DSS). Kurtzke scale is used to determine MS disability status. A score of 4 shows a limited walking ability but without aid or rest of more than 500m. A score of 6 shows the ability to walk with unilateral support no more than 100m without rest. A score of 7 shows the ability to walk no more than 10m without rest while leaning against a wall or holding onto furniture for support. Later on, an expanded disability status scale (EDSS) has been implemented (Kurtzke, 1983).

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of interest.

None declared.

References

  • 1.Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520–532. [DOI] [PubMed] [Google Scholar]
  • 2.Koch-Henriksen N, Sorensen PS. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere? J Neurol Sci 2011; 311: 58–63. [DOI] [PubMed] [Google Scholar]
  • 3.Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: Race, sex, and geography. Ann Neurol 2004; 55: 65–71. [DOI] [PubMed] [Google Scholar]
  • 4.Confavreux C. An unchanging man faced with changing times. Brain 2012; 135: 1663–1665. [DOI] [PubMed] [Google Scholar]
  • 5.Vukusic S, Van Bockstael V, Gosselin S, et al. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry 2007; 78: 707–709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Fromont A, Binquet C, Sauleau EA, et al. Geographic variations of multiple sclerosis in France. Brain 2010; 133: 1889–1899. [DOI] [PubMed] [Google Scholar]
  • 7.McLeod JG, Hammond SR, Kurtzke JF. Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: A reassessment. I. Risk of MS by age at immigration. J Neurol 2011; 258: 1140–1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kurtzke JF. Epidemiology in multiple sclerosis: A pilgrim’s progress. Brain 2013; 136: 2904–2917. [DOI] [PubMed] [Google Scholar]
  • 9.Besag J, York J, Mollié A. Bayesian image restoration, with two applications in spatial statistics. Ann Inst Stat Math 1991; 43: 1–20. [Google Scholar]
  • 10.Clayton D, Kaldor J. Empirical Bayes estimates of age-standardized relative risks for use in disease mapping. Biometrics 1987; 43: 671–681. [PubMed] [Google Scholar]
  • 11.Gangnon RE, Clayton MK. Bayesian detection and modeling of spatial disease clustering. Biometrics 2000; 56: 922–935. [DOI] [PubMed] [Google Scholar]
  • 12.Getis A, Ord JK. The analysis of spatial association by use of distance statistics. Geogr Anal 1992; 24: 189–206. [Google Scholar]
  • 13.Lucas RM, Ponsonby ALL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011; 76: 540–548. [DOI] [PubMed] [Google Scholar]
  • 14.Bjørnevik K, Riise T, Casetta I, et al. Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Mult Scler 2014; 20: 1042–1049. [DOI] [PubMed] [Google Scholar]
  • 15.Van der Mei IA, Ponsonby ALL, Blizzard L, et al. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001; 20: 168–174. [DOI] [PubMed] [Google Scholar]
  • 16.Van der Mei IA, Ponsonby ALL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. BMJ 2003; 327: 316. doi: 10.1136/bmj.327.7410.316. [DOI] [PMC free article] [PubMed]
  • 17.Orton SM, Wald L, Confavreux C, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011; 76: 425–431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kurtzke JF, Delasnerie-Lauprêtre N. Reflection on the geographic distribution of multiple sclerosis in France. Acta Neurol Scand 1996; 93: 110–117. [DOI] [PubMed] [Google Scholar]
  • 19.Simpson S, Jr, Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82: 1132–1141. [DOI] [PubMed] [Google Scholar]
  • 20.Ramagopalan SV, Hoang U, Seagroatt V, et al. Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: A descriptive study. J Neurol Neurosurg Psychiatry 2011; 82: 682–687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Delasnerie-Lauprêtre ND, Alpérovitch A. Childhood infections in multiple sclerosis: A study of North African-born patients who migrated to France. Neuroepidemiology 1990; 9: 118–123. [DOI] [PubMed] [Google Scholar]
  • 22.Yaouanq J, Tron I, Kerbrat A, et al. Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000–2001. Acta Neurol Scand 2015; 131: 321–328. [DOI] [PubMed] [Google Scholar]
  • 23.El Adssi H, Debouverie M, Guillemin F. Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method. Mult Scler 2012; 18: 1244–1250. [DOI] [PubMed] [Google Scholar]
  • 24.Sagnes-Raffy C, Gourraud PA, Hannon V, et al. La SEP en Haute-Garonne: Une sous-estimation importante du nombre de cas. Rev Epidemiol Sante Publique 2010; 58: 23–31. [DOI] [PubMed] [Google Scholar]
  • 25.Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–1438. [DOI] [PubMed] [Google Scholar]
  • 26.Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability: An amnesic process. Brain 2003; 126: 770–782. [DOI] [PubMed] [Google Scholar]
  • 27.Confavreux C, Vukusic S. L'évolution naturelle de la sclérose en plaques. Rev Prat 2006; 56: 1313–1320. [PubMed] [Google Scholar]
  • 28.Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment. Clin Neurol Neurosurg 2006; 108: 327–332. [DOI] [PubMed] [Google Scholar]
  • 29.Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900–1913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129: 595–605. [DOI] [PubMed] [Google Scholar]
  • 31.Berg-Hansen P, Celius EG. Socio-economic factors and immigrant population studies of multiple sclerosis. Acta Neurol Scand 2015; 132: S37–S41. [DOI] [PubMed] [Google Scholar]
  • 32.Goulden R, Ibrahim T, Wolfson C. Is high socioeconomic status a risk factor for multiple sclerosis? A systematic review. Eur J Neurol 2015; 22: 899–911. [DOI] [PubMed] [Google Scholar]

Articles from Multiple sclerosis journal - experimental, translational and clinical are provided here courtesy of SAGE Publications

RESOURCES